Chugai Pharmaceutical and GSK Sign Exclusive License Agreement for Anti-Dengue Antibody AID351
Japan-based Chugai Pharmaceutical has entered into an exclusive license agreement with British pharmaceutical company GlaxoSmithKline (GSK) for the anti-dengue virus antibody known as AID351, in a move that advances global efforts to combat one of the …